Design Therapeutics, Inc. Cash Flow Statement
DSGN|3 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Design Therapeutics, Inc. used $43M in operating cash flow and negative free cash flow of $43M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2021 |
|---|---|---|---|
| Net Income | -$49.6M | -$66.9M | -$8.3M |
| Depreciation & Amortization | $596.0K | $537.0K | $5.0K |
| Operating Cash Flow | -$43.1M | -$58.6M | -$8.7M |
| Capital Expenditures | $340.0K | $256.0K | $76.0K |
| Free Cash Flow | -$43.4M | -$58.8M | -$8.7M |
| FCF Margin | - | - | -3869.5% |